Chardan Capital Markets analyst Keay Nakae upgraded Dicerna Pharmaceuticals (NASDAQ: DRNA) from Neutral to Buy with a price target of ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE